drugset / Trial / NCT03983993
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
Phase 2
Active not recruiting
26 enrolled
Emory University
GlaxoSmithKline · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies the side effects and how well niraparib and panitumumab work in treating patients with colorectal cancer that has spread to other places in the body. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and panitumumab may work better in treating patients with colorectal cancer.
Timeline
- Start
- 2019-10-15
- Primary completion
- 2023-05-17
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niraparib | Small molecule | 200 mg | Oral |
| Subject | Niraparib | Small molecule | 300 mg | Oral |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | Intravenous |